Cell and Gene Therapy Forum: The Future of CGT Is Here – Navigating Commercialization Challenges

From 2021 to 2022, the cellular and gene therapy (CGT) industry gained remarkable momentum. Several gene therapy products were approved for market launch in China, bringing hope to patients. Meanwhile, multiple domestic companies successively received clinical trial approvals, marking the entry of the CGT industry into the clinical development stage. As the CGT sector accelerated its growth, market competition intensified rapidly, with various stakeholders eager to enter this promising field.

The 7th Future Healthcare Top 100 Conference, in collaboration with VCBeat New Medicine and CDH VGC, jointly hosted the Cell and Gene Therapy Forum. The forum focused on the deployment of innovative technologies at the source of innovation in the cell and gene therapy industry, as well as the challenging aspects of industrialization, exploring the future development potential and direction of the industry, and providing support for the growth of the cell and gene therapy sector.

2023 Future Healthcare 100 Conference, hosted by VB100, VCBeat, and Eggshell Research Institute, with strategic partnership support from Shanghai Zhangjiang Group, will be grandly held at the Shanghai Zhangjiang Science Hall from May 5–7, 2023. Led by Academician Robert Langer and IEEE scientists, nearly 500 industry leaders will convene for three main forums and 31 trending thematic sessions!